4. ETIOLOGY
MEN2A syndrome affects 60% to 90% of MEN2 families while MEN2B affects only 5% of
MEN2 families. All of these conditions are due to one of the several RET proto-oncogene
mutations which play an important role in the growth and differentiation of the structures
mostly evolved from neural crest cells
5.
6. EPIDEMIOLOGY
The prevalence of all MEN2 worldwide is 1 in 35,000, while in the United
States, it is 1 in 30,000 to 50,000. The epidemiology of MEN2B is unknown. The
prevalence of MEN2B is estimated to be between 1 in 600,000 to 1 in 4 million.
In MEN2A patients, 50% of those with RET gene mutations develop disease by
age 50 years, and 70% develop the disease by age 70 years. MTC has been
detected shortly after birth in MEN2B
7. MEDULLARY THYROID CANCER
medullary thyroid carcinoma is a tumor of the
parafollicular cells (C cells) derived from the neural
crest. It is characterized by an amyloid stroma.
Many medullary tumors produce high levels of serum
calcitonin and carcinoembryonic antigen, Levels fall
after resection and rise again with recurrence making it
a valuable tumor marker in the follow up of patients
with this disease
8. MTC
Clinical presentation :
• Neck mass usually a firm, smooth and distinct lump in the neck, indistinguishable from any other form of
thyroid solitary nodule
• Pain or aching is more common in these tumors when compared to others
• Dyspnea , dysphonia , dysphagia in case of local invasion
• Diarrhea is a feature in 30% of cases and this may be due to 5-hydroxytryptamine or prostaglandins
produced by the tumor cells occurs in affected individuals with a plasma calcitonin concentration >10
ng/mL and implies a poor prognosis
• Flushing
Diagnosis :
Usually made by FNA
9. MTC
In general 10-20% of all cases of MTC are familial
The familial form frequently affects children and young adults whereas sporadic cases occur
at any age with no sex predominance
If it occurs in combination with hyperparathyroidism and pheochromocytoma = MEN 2A
When the familial form is associated with prominent mucosal neuromas involving the lips
tongue and inner aspects of the eyelids with marfanoid habitus = MEN 2B
Involvement of lymph nodes occurs in 50-60% of cases and blood borne metastases are
common
It is not TSH dependent and do not take up radioactive iodine
The prognosis is variable and depends on the stage at diagnosis
10. MTC TREATMENT
• total thyroidectomy
• prophylactic or therapeutic resection of the central and bilateral lymph
nodes
In general
• detected by genetic screening for RET gene mutations
• Estimation of serum calcitonin levels in the basal state and after
stimulation by Ca
• If there is a rise in calcitonin after stimulation test thyroidectomy
should be done
• Prophylactic surgery is now recommended for infants with genetic
trait
Familial cases
• In all cases before embarking upon thyroid surgery, pheochromocytoma
must be excluded by measurement of urinary catecholamine levels
Other measures
11.
12. PHEOCHROMOCYTOMA
These are tumors of the adrenal medulla and sympathetic ganglia that are
derived from chromaffin cells and most commonly produce supraphysiological
levels of circulating catecholamines.
Pheochromocytoma, a typically benign adrenal medullary tumor (usually
bilateral and multicentric), occurs in 40% to 50% of patients with MEN2A or
MEN2B; the frequency and penetration highly depend on the specific type of
mutation
Usually, it is identified as a part of the screening process in the patients with
known or suspected MEN2
13. PHEOCHROMOCYTOMA – PATHOLOGY
• Phaeochromocytomas are greyish-pink on the cut surface and are usually highly
vascularised. Areas of hemorrhage or necrosis are often observed
• Microscopically, tumor cells are polygonal but the configuration varies considerably
• These tumors produce calcitonin, ACTH, vasoactive intestinal polypeptide (VIP) and
parathyroid hormone-related protein (PTHrP).
• In patients with MEN 2, the onset of phaeochromocytoma is preceded by adrenomedullary
hyperplasia, sometimes bilateral.
• Phaeochromocytoma is rarely malignant in MEN 2
16. PHEOCHROMOCYTOMA – DIAGNOSIS
-metanephrine and normetanephrine level, in a 12 or 24-hour urine
collection,)
-determination of plasma-free metanephrine and normetanephrine levels
localisation of the phaeochromocytoma. MRI is preferred because
contrast media used for CT scans can provoke paroxysms.
Classically, phaeochromocytomas show a ‘Swiss cheese’ configuration
- (SPECT) will identify about 90% of primary tumours and is essential for the
detection of multiple extra-adrenal tumors and metastases
- (PET) for metastases
- (DOPA) is yet more sensitive in detecting metastatic foci.
17. Magnetic resonance imaging of a sporadic
phaeochromocytoma of the left adrenal gland
(arrowheads).
Meta-iodobenzylguanidine (MIBG) single-
photon emission computed tomography scan
of a phaeochromocytoma of the left
adrenal gland (arrow) in the same patient as in
18. PHEOCHROMOCYTOMA- TREATMENT
Laparoscopic resection is now routine in the treatment of
pheochromocytoma
If the tumor is larger than 8-10cm or radiological signs of
malignancy are detected an open approach should be considered
19.
20. Pre-op
• α- adrenoreceptor blocker (phenoxybenzamine) should be used
• β-blockade is required if tachycardia or arrhythmias develop
Per-op
• A central venous catheter and invasive arterial monitoring are used. Special attention
is required when the adrenal vein is ligated as a sudden drop in blood pressure may
occur
• The infusion of large volumes of fluid or administration of noradrenaline can be
necessary to correct postoperative hypotension in the presence of unopposed α-
blockade.
Post-op
• Patients should be observed for 24 hours in the intensive care (ICU) or high
dependancy unit as hypovolaemia and hypoglycaemia may occur.
• Lifelong yearly biochemical tests should be performed to identify recurrent, metastatic
or metachronous phaeochromocytoma
21. HYPEPARATHYROIDISM
PHPT occurs in approximately 20% of patients and is associated with mutations in codon
634 in the RET proto-oncogene
The majority of patients will be asymptomatic, with a mild elevation in calcium and
asymmetrically enlarged parathyroid glands
It is extremely important that the presence of a phaeochromocytoma is excluded prior to
surgical intervention
Surgery is usually performed for medullary thyroid carcinoma (MTC), with the parathyroid
enlargement often being a coincidental intraoperative finding
In this setting, with extensive surgery for MTC, the primary aim of treatment is to avoid
hypoparathyroidism. A conservative stance is adopted with resection of grossly enlarged
glands, but with preservation of parathyroid tissue where possible and identification with a
marking stitch in the neck
22.
23. OTHER MANIFESTATIONS
Patients with MEN2B tend to
have mucosal neuromas,
which are often located on
the lips, tongue, and buccal
mucosa. Other manifestations
include various skeletal and
ophthalmologic anomalies.
Marfanoid habitus, congenital
dislocation of the hip, pes
planus, pes cavus, pectus
excavatum, and kyphosis can
all be seen.
24.
25. MEN2A CLA
Cutaneous lichen amyloidosis (CLA)
also termed lichen planus amyloidosis
(LPA), is a rare skin condition that is
associated with MEN2A. It is thought to
be a primary neuropathy and presents
with pruritic, pigmented, scaly papules
usually in extensor surfaces of
extremities and interscapular region.
Histology has shown amyloid
deposition
26. MEN2A HD
Hirschsprung disease (HD), also
known as chronic aganglionic
megacolon, also is associated with
MEN2A. It is characterized by the
absence of autonomic ganglion
cells within the parasympathetic
chain of the sigmoid colon,
resulting in peristalsis, chronic
obstruction, and megacolon
28. CLINICAL CRITERIA
MEN2A
• is diagnosed clinically by the occurrence of two or more specific endocrine tumors ( MTC, pheochromocytoma, or
parathyroid adenoma/hyperplasia) in a single individual or in close relatives.
FMTC
• is diagnosed in families with four or more cases of MTC in the absence of pheochromocytoma or parathyroid
adenoma/hyperplasia.
MEN2B
• is diagnosed clinically by the presence of early-onset MTC, mucosal neuromas of the lips and tongue, as well as
medullated corneal nerve fibers, distinctive facies with enlarged lips, and an asthenic, marfanoid body habitus.
29. ESTABLISHING THE DIAGNOSES
When the phenotypic and laboratory findings suggest the diagnosis of MEN 2,
molecular genetic testing approaches can include single-gene panel testing or
use of a multigene panel
Molecular Genetic Testing Used in MEN 2 :
Gene 1 Method 2
Proportion of Probands with a Pathogenic Variant 3 Detectable
by Method
MEN 2A FMTC MEN 2B
RET
Sequence
analysis 4, 5 >98% 6, 7 >95% 6, 8 >98% 9
Sequence analysis
of select exons
98% 6, 10 95% 6, 8
Targeted analysis
for pathogenic 98% 9
30. EVALUATION FOLLOWING INITIAL DX
Referral to an endocrinologist
Consultation with a clinical geneticist and/or genetic counselor
Biochemical evaluations:
Plasma calcitonin
Plasma catecholamines and metanephrines
Serum calcium and parathyroid hormone
Evaluation for metastatic disease in individuals with MTC
CT with contrast for chest and abdomen
MRI of liver in the presence of nodal disease or calcitonin >400 pg/mL
31. PREVENTION OF PRIMARY MANIFESTATIONS
For MTC
* Prophylactic thyroidectomy is the primary
preventive measure for individuals with an
identified germline RET pathogenic variant
* Prophylactic thyroidectomy is safe for all age
groups; however, the timing of the surgery is
controversial
For all individuals with a RET pathogenic variant who
not had a thyroidectomy, annual biochemical screening is
recommended with immediate thyroidectomy if results are
abnormal
Annual serum calcitonin screening should begin at age:
- Six months for children with MEN 2B;
- Three to five years for children with MEN 2A or FMTC.
32. Pheochromocytoma
annual biochemical screening is recommended, followed by MRI and/or CT if the
biochemical results are abnormal
MEN 2A. Annual biochemical screening beginning at age eight years has been
recommended for individuals with a pathogenic variant in codons 630 and 634 and at age
20 years for a pathogenic variant in all other codons
FMTC. Screening as for MEN 2A is indicated, as not all families classified as FMTC are MTC-
only
MEN 2B. Annual screening should begin at age eight years .
33. Parathyroid adenoma or hyperplasia
Annual biochemical screening is recommended for affected individuals who have not
had parathyroidectomy and parathyroid autotransplantation.
MEN 2A. Screening should start at age eight years for individuals with a pathogenic variant in
codons 630 and 634, and by age 20 years for individuals with other RET pathogenic variants
FMTC. Periodic screening should begin at age 20 years
MEN 2B. Screening is unnecessary as individuals with MEN 2B are not at increased risk for
hyperparathyroidism.
34. SUGGESTED FOLLOW UP (SUMMARY)
Biochemical
Screening
Indication for imaging Imaging Indication for
Surgery
MTC Annual calcitonin (or
stimulated calcitonin)
• Rise in calcitonin
• Palpable lump
Ultrasound/CT/M
RI, 99mTc
Sestamibi
scanning
• At presentation
in adulthood
(exclude Phaeo
first)
Phaeo Annual 24hr urinary
metanephrines
• 3-5 yearly
• Or if meta
nephrines elevated
CT/MRI, MIBG • Positive scan
Parathyroid Annual PTH and
ionised calcium
• Development of
hyperparathyroid
ism
• And renal
calculi,
osteoporosis,
symptomatic
hypercalcaemia,
or patient
preference
35. GENETIC COUNSELING
Genetic counseling is the process of providing individuals
and families with information on the nature, mode of
inheritance, and implications of genetic disorders to help
them make informed medical and personal decisions.
Notas del editor
Multiple endocrine neoplasia type 2 (MEN 2) is a hereditary canc
MEN 2A is diagnosed clinically by the occurrence of two or more specific endocrine tumors (medullary thyroid carcinoma [MTC], pheochromocytoma, or parathyroid adenoma/hyperplasia) in a single individual or in close relatives.
FMTC is diagnosed in families with four or more cases of MTC in the absence of pheochromocytoma or parathyroid adenoma/hyperplasia.
MEN 2B is diagnosed clinically by the presence of early-onset MTC, mucosal neuromas of the lips and tongue, as well as medullated corneal nerve fibers, distinctive facies with enlarged lips, and an asthenic, marfanoid body habitus
er syndrome associated primarily with tumors of the adrenal gland, thyroid and parathyroid.
Point mutations associated with MEN2A and the FMTC-only subtype have been identified in exons 10 and 11. Evidence of genotype/phenotype correlation exists. Classical MEN2A is associated with germline missense mutations in RET codons 609, 611, 618, or 620 of exon 10 or codon 634 of exon 11, which map to the receptor’s extracellular cysteine-rich domain. MEN2A with cutaneous lichen amyloidosis is nearly always associated with mutation of codon 634, while patients with MEN2A and Hirschsprung disease typically harbor mutations involving RET exon 10. [10]
Approximately 75% of MEN2B cases are sporadic and affected patients have de novo RET mutations, while 25% of cases occur in families with previous or current manifestations of MEN2B. Approximately 95% of patients with MEN2B have RET germline mutations in exon 16 (codon M918T) and fewer than 5% have RET germline mutations in exon 15 (codon A883F). [1]
The rearranged during transfection (RET) protein is a receptor tyrosine kinase that is localized to chromosome 10q11.2. It appears to transduce growth and differentiate signals in several tissues, particularly those arising from neural crest cells. Some cytogenetic mutations have been reported; these may involve intracellular and extracellular domains of the RET protein signaling pathway. The germline RET mutations in MEN2 result in a gain of function of this tyrosine kinase receptor. This is different from many other inherited predispositions to neoplasia that are due to heritable "loss-of-function" mutations that inactivate tumor suppressor proteins.
Levels fall after resection and rise again with recurrence making it a valuable tumour marker in the follow up of patients with this disease
Treatment is by total thyroidectomy and prophylactic or therapeutic resection of the central and bilateral lymph nodes
Familial cases are detected by genetic screening for RET gene mutations
Medullary thyroid carcinoma (MTC). Standard treatment for MTC is surgical removal of the thyroid and lymph node dissection [Kloos et al 2009, National Comprehensive Cancer Network 2015]. Current NCCN guidelines recommend consideration of therapeutic external beam radiation therapy or intensity-modulated radiation therapy for incomplete tumor resection or extrathyroidal extension with positive margins [National Comprehensive Cancer Network 2015]. Several kinase inhibitors – vandetanib, cabozantinib, and BLU-667 – have improved progression-free survival and in some cases cause disease regression in unresectable or advanced metastatic MTC [Elisei et al 2013, Wells et al 2013, Subbiah et al 2018].
All individuals who have undergone thyroidectomy need thyroid hormone replacement therapy.
Autotransplantation of parathyroid tissue is not typically performed at the time of thyroidectomy unless there is evidence of hyperparathyroidism [
Usually, it is identified as a part of the screening process in the patients with known or suspected MEN2. One must always take care of bilateral or extra-renal pheochromocytoma. Although it is rare for pheochromocytoma to appear before MTC, it can be the initial manifestation of MEN2 with the classic symptoms of pheochromocytoma such as paroxysmal attacks of a headache, anxiety, diaphoresis, and palpitations. The mean age of presentation is 25 to 32 years, and it may appear as early as 8 to 12 years of age.[6]
Phaeochromocytomas are greyish-pink on the cut surfaceand are usually highly vascularised. Areas of haemorrhage ornecrosis are often observed
Microscopically,tumour cells are polygonal but the configuration varies considerably
produce calcitonin,ACTH, vasoactive intestinal polypeptide (VIP) and parathyroid hormone-related protein (PTHrP).
patients withMEN 2, the onset of phaeochromocytoma is preceded byadrenomedullary hyperplasia, sometimes bilateral. Phaeochromocytoma is rarely malignant in MEN 2.
Symptoms and signs are caused by catecholamine excessand are typically intermittent (Table 52.2). In total, 90% ofpatients with the combination of headache, palpitations andsweating in the presence of an adrenal tumour have a phaeochromocytoma. Paroxysms may be precipitated by physical training, induction of general anaesthesia and numerousdrugs and agents (contrast media, tricyclic antidepressivedrugs, metoclopramide and opiates). Hypertension may occurcontinuously, be intermittent or absent. A subset of patientsare asymptomatic. More than 25% of apparently sporadicphaeochromocytomas are caused by germline mutations inthe RET, SDHB, SDHC, SDHD and NF1 genes; genetic testing for these and other genes is therefore recommended, particularly in those patients aged under 50 years
DiagnosisThe first step in the diagnosis of a phaeochromocytoma is theconfirmation of excessive catecholamine levels in the patienteither by the measurement of adrenaline and noradrenalinebreakdown products, metanephrine and normetanephrinelevel, in a 12 or 24-hour urine collection, (levels that exceedthe normal range by 2–40 times will be found in affectedpatients) or by determination of plasma-free metanephrineand normetanephrine levels. Biochemical tests should beperformed at least twice. The biochemical diagnosis is thenfollowed by localisation of the phaeochromocytoma. MRIis preferred because contrast media used for CT scans canprovoke paroxysms. Classically, phaeochromocytomas show
a ‘Swiss cheese’ configuration (Figure 52.11).
123I-MIBG(metaiodobenzylguanidine) single-photon emission computed tomography (SPECT) will identify about 90% of primary tumours and is essential for the detection of multiple extra-adrenal tumours and metastases (Figure 52.12). Positron emission tomography (PET) scanning using fluorodeoxyglucose (FDG) or dihydroxyphenylalanine (DOPA) is yet more sensitive in detecting metastatic foci.T
Pheochromocytomas detected by biochemical testing and radionuclide imaging are removed by adrenalectomy, which may be performed using video-assisted laparoscopy. Historically, some specialists recommended bilateral adrenalectomy at the time of demonstration of tumor on just a single adrenal gland because of the strong probability that the other adrenal gland would develop a tumor within ten years. However, because of the risk for adrenal insufficiency and Addisonian crisis following bilateral adrenalectomy, most experts now recommend unilateral adrenalectomy in unilateral tumors and cortical-sparing adrenal surgery with close monitoring of the remnant tissue in persons with one remaining adrenal gland or bilateral pheochromocytoma [Kloos et al 2009, Neumann et al 2019].
Hypertensive treatment prior to adrenalectomy often involves the use of α- and β-adrenergic receptor blockade [Pacak et al 2005], although some centers do not pretreat with α-blockade and use nitroprusside to control blood pressure during surgery [Neumann et al 2019].
The operative approach is laparoscopy or retroperitoneoscopy.
Unilateral or bilateral subtotal resection may be feasible, which
retains the healthy part of the gland and prevents postoperative
dependence on cortisol and mineralocorticoid supplementation
Further phaeos can develop in the remnants that are left so continued surveillance is required.
α- adrenoreceptor blocker (phenoxybenzamine) should be used to block the effects of catecholamine excess and its consequencesduring surgery.
Additional β-blockade is required if tachycardia or arrhythmias develop; this should not be introduced until the patient is α-blocked.
With adequate α-blockade preoperatively, anaesthesia should not be more hazardous than in patients with a non-functioning adrenal tumour
A central venous catheter and invasive arterial monitoring are used. Special attention is required when the adrenal vein is ligated as a sudden drop in blood pressure mayoccur
The infusion of large volumes of fluid or administrationof noradrenaline can be necessary to correct postoperative hypotension in the presence of unopposed α-blockade.
Patients should be observed for 24 hours in the intensive care (ICU) or high dependancy unit as hypovolaemia and hypoglycaemia may occur. Lifelong yearly biochemical tests should be performed to identify recurrent, metastatic or metachronous phaeochromocytoma
Parathyroid adenoma or hyperplasia diagnosed at the time of thyroidectomy is treated either with resection of the visibly enlarged parathyroid gland(s), subtotal parathyroidectomy, or total parathyroidectomy with forearm autograft [Kloos et al 2009]. However, in most individuals with MEN 2A, hyperparathyroidism is diagnosed many years after thyroidectomy.
Individuals with biochemical evidence of primary hyperparathyroidism who have undergone prior thyroidectomy should have preoperative localization with excision of the localized hypertrophied parathyroid glands and forearm autotransplantation.
Therapy with medications to control primary hyperparathyroidism should be considered in individuals with a high risk for surgical mortality, limited life expectancy, or persistent or recurrent primary hyperparathyroidism after one or more surgical attempts [Kloos et al 2009].
MEN 2A-associated hyperparathyroidismMEN 2A consists of medullary thyroid carcinoma, unilateralor bilateral phaeochromocytomas and PHPT. PHPT occurs inapproximately 20% of patients and is associated with mutations in codon 634 in the RET proto-oncogene. The majority of patients will be asymptomatic, with a mild elevation incalcium and asymmetrically enlarged parathyroid glands. Itis extremely important that the presence of a phaeochromocytoma is excluded prior to surgical intervention. Surgery isusually performed for medullary thyroid carcinoma (MTC),with the parathyroid enlargement often being a coincidentalintraoperative finding. In this setting, with extensive surgeryfor MTC, the primary aim of treatment is to avoid hypoparathyroidism. A conservative stance is adopted with resectionof grossly enlarged glands, but with preservation of parathyroid tissue where possible and identification with a markingstitch in the neck
Parathyroidectomy with exposure of the left superiorand inferior parathyroid glands (white arrows) in situ (a) and left superior gland mobilised on its vascular pedicle (b).
To reduce the risk of postoperative hypocalcemia, remove only grossly abnormal parathyroid glands. If all parathyroid glands are enlarged, a subtotal parathyroidectomy is advocated, leaving an approximately 60-mg remnant. Perform a cervical thymectomy because of the increased risk of supernumerary parathyroid glands. [20]
Multiple endocrine neoplasia type 2 (MEN 2) includes the phenotypes MEN 2A; familial medullary thyroid carcinoma (FMTC), which may itself be a variant of MEN 2A; and MEN 2B.
MEN 2A should be suspected in individuals with one or more specific endocrine tumors: medullary thyroid carcinoma (MTC), pheochromocytoma, or parathyroid adenoma/hyperplasia.
FMTC should be suspected in families with more than one individual diagnosed with MTC in the absence of pheochromocytoma or parathyroid adenoma/hyperplasia.
MEN 2B should be suspected in individuals with distinctive facies including lip mucosal neuromas resulting in thick vermilion of the upper and lower lip, mucosal neuromas of the lips and tongue, medullated corneal nerve fibers, marfanoid habitus, and MTC.
MEN2A and MEN2B should be suspected in any patient diagnosed with MTC or pheochromocytoma, particularly when the age of presentation is very young (younger than 35). MTC most commonly presents with a solitary thyroid nodule and/or cervical lymphadenopathy. Any patient with diagnosed MTC or family history of MTC should be tested for RET proto-oncogene mutations for both MEN2A and MEN2B. The patients who are diagnosed with pheochromocytoma at the age earlier than that of its sporadic forms should be tested for MEN2A and MEN2B. The classic symptoms of pheochromocytoma are the paroxysms of a headache, anxiety, diaphoresis and palpitations, and high blood pressure. The presence of these symptoms in the third decade, particularly in between 25 and 32 years, should prompt to screen for MEN2.
A detailed history of the presence of associated conditions (described above) in the patient or the family members should be taken. Other possible physical examination findings include marfanoid habitus (decreased upper to lower body ratio), mucosal neuromas (red papules) over lips and tongues, and joint hyperlaxity associated with MEN2B. The patients typically lack lens dislocation or aortic abnormalities, unlike Marfan syndrome. MEN2A also is suspected in patients with clinical features like purity, scaly, pigmented papules in the interscapular region as these are features of CLA that have an association with MEN2A.
Patients with classic clinical manifestations of MEN2 are evaluated for two main reasons:
To screen for other associated common tumors to decrease overall morbidity and mortality
To screen for genetic mutation so that other family members should be tested and provided adequate prophylactic medical and surgical care such as prophylactic thyroidectomy
The diagnosis of MEN 2 is established in a proband with the following clinical criteria. Identification of a heterozygous germline RET pathogenic variant by molecular genetic testing (see Table 1) establishes the diagnosis if clinical features are inconclusive.
To establish the extent of disease and needs in an individual diagnosed with multiple endocrine neoplasia type 2 (MEN 2), the following evaluations are recommended if they have not already been completed:
Patients should be monitored on a lifelong basis for evidence of recurrent disease. After an initial follow-up visit, patients may be evaluated at 6 months, then yearly if they are asymptomatic.
Evaluations should include the following:
Physical examination
24-hour urine catecholamine, metanephrine and vanillylmandelic acid levels
CEA level
Calcitonin level
Serum calcium level.
If recurrent hypercalcemia is suggested, consider patients for repeat cervical exploration.
If pheochromocytoma is suggested, evaluate patients for surgical resection. This tumor is likely in the remaining contralateral adrenal, although workup should include a CT scan and an MIBG scan to evaluate for recurrence at the resected area or at an extra-adrenal site. Recurrences in the resected area are more common if a subtotal adrenalectomy had been performed initially.
The management of patients with calcitonin/CEA elevations has been controversial. Resect any palpable cervical disease. Some practitioners have advocated routine cervical ultrasonography with exploration for any evidence of recurrence. Many patients remain asymptomatic with elevated calcitonin levels for 20 years or longer.
So here we are talking about patients who have been detected to have the gene mutations but noplasms have not yet developed
So there are some prophylactic measures that can be taken to prevent the development of these neoplasms primarly
Prior to any surgery, the presence of a functioning pheochromocytoma should be excluded by appropriate biochemical screening in any individual with MEN 2A or MEN 2B. In a prospective study of at-risk family members with the pathogenic variant, 8% had pheochromocytoma detected at the same time as MTC [Nguyen et al 2001].
If pheochromocytoma is detected, adrenalectomy should be performed before thyroidectomy to avoid intraoperative catecholamine crisis [Lee & Norton 2000].
Parathyroid adenoma or hyperplasia. Annual biochemical screening is recommended for affected individuals who have not had parathyroidectomy and parathyroid autotransplantation.
MEN 2A. Screening should start at age eight years for individuals with a pathogenic variant in codons 630 and 634, and by age 20 years for individuals with other RET pathogenic variants
FMTC. Periodic screening should begin at age 20 years
MEN 2B. Screening is unnecessary as individuals with MEN 2B are not at increased risk for hyperparathyroidism.